Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

862.86 +18.36 (+2.17%)
Official Closing Price Updated: 7:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Why Bio-Techne (TECH) Stock Is Up Today
Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment... 
Via StockStory
Topics Artificial Intelligence Supply Chain World Trade
Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say
Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on strong obesity drug momentum. 
Via Benzinga
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
Earnings Scheduled For October 30, 2025
 
Via Benzinga
AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to... 
Via TokenRing AI
Topics Artificial Intelligence Intellectual Property
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Why iRhythm (IRTC) Stock Is Trading Up Today
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 3.2% in the afternoon session after it reported strong third-quarter financial results that surpassed expectations and... 
Via StockStory
Topics Artificial Intelligence World Trade
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
Novartis is set to boost its developmental pipeline with this acquisition. 
Via The Motley Fool
Meta Meltdown Sends Nasdaq Tumbling as Apple Shines After Hours
Wall Street slipped on Thursday as disappointing results from Meta and cautious tones from the Fed weighed on sentiment. But after the closing bell, Apple’s record-breaking numbers helped restore a bit... 
Via Chartmill
Topics Economy
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
1 Healthcare Stock with Impressive Fundamentals and 2 We Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Twilio Stock Rises On Q3 Earnings Beat, Raised Guidance
Twilio stock rose after the software maker reported Q3 earnings that topped estimates and hiked its full-year revenue outlook. 
Via Investor's Business Daily
Topics Artificial Intelligence Earnings
Cloudflare Earnings Top Estimates. Revenue Outlook Above Views.
Cloudflare stock wavered after the company reported Q3 earnings that topped estimates and guidance came in slightly above views. 
Via Investor's Business Daily
Topics Artificial Intelligence
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
'Our GPUs Are Everywhere’ According to CEO Jensen Huang as Nvidia Doubles Down on AI, Quantum, and 6G
Nvidia stock continues to surge higher as the AI chipmaker widens its moat significantly. 
Via Barchart.com
Topics Artificial Intelligence
Eli Lilly (LLY) Stock Trades Up, Here Is Why
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the company reported a "beat and raise" quarter. 
Via StockStory
Topics Artificial Intelligence Economy Government
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera. 
Via Investor's Business Daily
Topics Economy Government
Nvidia's $5 Trillion Milestone Turns These AI ETFs Into Hot Trades
Nvidia's $5 trillion valuation record is igniting momentum across semiconductor and AI-themed ETFs as investors chase the next leg of the chip supercycle. 
Via Benzinga
Topics Artificial Intelligence ETFs
Tech Titans Tumble, Alphabet Soars as Market Opens Mixed on AI Spending Jitters
The U.S. stock market opened with a palpable sense of divergence on October 30, 2025, as investors grappled with a mixed bag of quarterly earnings and forward-looking statements from the nation's... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
Eli Lilly (LLY) Q3 2025 Earnings Call Transcript
Eli Lilly (LLY) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide
CEO Dave Ricks told CNBC that the first study the company plans to read out for Retatrutide will be on knee pain. 
Via Stocktwits
Navigating the Currents: Dow Jones Shows Resilience Amidst Fed's Caution and Geopolitical Shifts
The Dow Jones Industrial Average (DJIA) finds itself navigating a complex economic landscape as of October 30, 2025, exhibiting resilience despite a barrage of mixed signals from central bank policies,... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast
Eli Lilly reported Q3 revenue of $17.6 billion, beating estimates and raising 2025 guidance as Mounjaro and Zepbound sales surged. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
 
Via Benzinga
Eli Lilly Delivers Strong Q3 Performance, Raises Earnings Outlook
Eli Lilly’s Q3 2025 revenue jumped 54% to $17.6 billion with adjusted EPS of $7.02, prompting the company to lift its full-year guidance. 
Via Talk Markets
These S&P500 stocks are moving in today's pre-market session
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session. 
Via Chartmill
Eli Lilly & Co (NYSE:LLY) Q3 2025 Earnings Beat Estimates, Fueling Pre-Market Rally
Eli Lilly's Q3 2025 results crushed estimates, driven by high demand for Mounjaro and Zepbound. The company raised its full-year outlook, sparking a stock rally. 
Via Chartmill
Topics Earnings
Eli Lilly Blows Past Expectations On The Back Of Mounjaro, Zepbound
Shares jumped early Thursday after the drugmaker easily topped third-quarter forecasts. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.